シノバックもファイザーも凄いアルね！＠今年三月＠香港

香港でのシノバック、ファイザー社ワクチンのオミクロンに対する効果。ファイザーの方は2回接種でも90%前後の死亡/重症化予防効果で(左)、シノバックでは若年で90%である一方高齢者では60-80%。3回接種なら98%前後と優秀。死亡例は未接種が多い(右)。シノバックもかなり良い。https://t.co/UFrMuAtKgo pic.twitter.com/CvQVv3oDbH

— ペン二郎 (@morilyn1123) March 23, 2022

 

Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong

Martina E. McMenamin, Joshua Nealon, Yun Lin, Jessica Y. Wong, Justin K. Cheung, Eric H. Y. Lau, Peng Wu, Gabriel M. Leung, Benjamin J. Cowling

doi: https://doi.org/10.1101/2022.03.22.22272769

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Abstract

Background Hong Kong maintained extremely low circulation of SARS-CoV-2 until a major community epidemic of Omicron BA.2 starting in January 2022. Both mRNA BNT162b2 (BioNTech/Fosun Pharma) and inactivated CoronaVac (Sinovac) vaccines are widely available, however coverage has remained low in older adults. Vaccine effectiveness in this predominantly infection-naïve population is unknown.


Methods We used individual-level case data on mild/moderate, severe/fatal and fatal hospitalized COVID-19 from December 31, 2021 to March 8, 2022, along with census information and coverage data of BNT162b2 and CoronaVac. We used a negative binomial model, adjusting for age and calendar day to estimate vaccine effectiveness of one, two and three dose schedules of both vaccines, and relative effectiveness by number of doses and vaccine type.


Findings A total of 12.7 million vaccine doses were administered in Hong Kong’s 7.3 million population, and we analyzed data from confirmed cases with mild/moderate (N=5,474), severe/fatal (N=5,294) and fatal (N=4,093) COVID-19. Two doses of either vaccine protected against severe disease and death, with higher effectiveness among adults ≥60 years with BNT162b2 (VE: 88.2%, 95% confidence interval, CI: 84.4%, 91.1%) compared to CoronaVac (VE: 74.1%, 95% CI: 67.8%, 79.2%). Three doses of either vaccine offered very high levels of protection against severe outcomes (VE: 98.1%, 95% CI: 97.1%, 98.8%).


Interpretation Third doses of either BNT162b2 or CoronaVac provide substantial additional protection against severe COVID-19 and should be prioritized, particularly in older adults who received CoronaVac primary schedules. Longer follow-up is needed to assess persistence of different vaccine platforms and schedules.


Funding COVID-19 Vaccines Evaluation Program, Chinese Center for Disease Control and Prevention
Competing Interest Statement

BJC reports honoraria from AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. JN was previously employed by and owns shares in Sanofi. The authors report no other potential conflicts of interest.
Funding Statement

This project was supported by the China CDC-sponsored COVID-19 Vaccines Evaluation Program (COVEP). BJC is supported by the Theme-based Research Scheme (project no. T11-712/19-N) from the Research Grants Council from the University Grants Committee of Hong Kong, and an RGC Senior Research Fellowship (grant number: HKU SRFS2021-7S03).

https://www.medrxiv.org/content/10.1101/2022.03.22.22272769v1

 AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur

China CDC-sponsored COVID-19 Vaccines Evaluation Program (COVEP)

2022年11月29日火曜日

非国民の大多数を占める爺婆に接種させまくるアルね！

https://tokumei10.blogspot.com/2022/11/blog-post_319.html

 

2022年11月24日木曜日

中国大敗北　新型コロナに

https://tokumei10.blogspot.com/2022/11/blog-post_43.html

、、、（爆ｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗ